Florida International University.
Florida International University.
Behav Ther. 2021 Sep;52(5):1171-1187. doi: 10.1016/j.beth.2021.01.004. Epub 2021 Feb 18.
Despite recent advances in the treatment of early child social anxiety, the broad accessibility of brick-and-mortar services has been limited by traditional barriers to care, and more recently by new obstacles related to efforts to slow the spread of COVID-19. The present waitlist-controlled trial examined the preliminary efficacy of a family-based behavioral parenting intervention (i.e., the iCALM Telehealth Program) that draws on Parent-Child Interaction Therapy and videoconferencing to remotely deliver clinician-led care for anxiety in early childhood. Young children (3-8 years) with a diagnosis of social anxiety disorder (N = 40; 65% from ethnic/racial minority backgrounds) were randomly assigned to iCALM or waitlist. Intent-to-treat analyses found that at post, independent evaluators classified roughly half of the iCALM-treated children, but only 6% of waitlist children, as "Responders" (Wald test = 4.51; p = .03). By Post, iCALM led to significantly greater reductions than waitlist in child anxiety symptoms, fear, discomfort, and anxiety-related social impairment, and also led to greater improvements in child soothability. By 6-month follow-up, the percentage of iCALM-treated children classified as "Responders" rose to roughly 60%. Exploratory moderation tests found iCALM was particularly effective in reducing life impairments and parental distress among families presenting with higher, relative to lower, levels of baseline parental accommodation. The present findings add to a growing body of research supporting the promise of technology-based strategies for broadening the portfolio of options for delivering clinician-led mental health services.
尽管早期儿童社交焦虑症的治疗方法最近有所进展,但传统的护理障碍以及最近与减缓 COVID-19 传播相关的新障碍,限制了实体服务的广泛普及。本项等待名单对照试验检验了一种基于家庭的行为养育干预(即 iCALM 远程医疗计划)的初步疗效,该干预措施借鉴了亲子互动疗法和视频会议,远程为儿童提供焦虑症的临床医生主导的护理。患有社交焦虑症(N=40;65%来自族裔/种族少数背景)的幼儿(3-8 岁)被随机分配到 iCALM 或等待名单组。意向性治疗分析发现,在治疗后,独立评估者将大约一半的 iCALM 治疗儿童(而等待名单组只有 6%)归类为“应答者”(Wald 检验=4.51;p=0.03)。与等待名单组相比,iCALM 治疗后儿童的焦虑症状、恐惧、不适和与焦虑相关的社交障碍显著减轻,儿童的安抚能力也显著提高。到 6 个月随访时,被归类为“应答者”的 iCALM 治疗儿童的比例上升到约 60%。探索性调节测试发现,对于基线父母适应能力较高(相对于较低)的家庭,iCALM 尤其能有效减少生活障碍和父母困扰。本研究结果为越来越多的支持基于技术的策略在扩大提供临床医生主导的心理健康服务的选择范围方面具有前景的研究提供了补充。